

Global Influenza Vaccines Market and Forecasts 2024 – 2032

<https://marketpublishers.com/r/G8A78B0E1789EN.html>

Date: January 2024

Pages: 310

Price: US\$ 3,500.00 (Single User License)

ID: G8A78B0E1789EN

Abstracts

The global influenza vaccines market size was valued at USD 7.8 Billion in 2023 and is likely to reach USD 13.7 Billion in 2032, expanding at a CAGR 7.2% during the forecast period.

Several factors are contributing to the growth of the influenza vaccines market. Here are some key factors:

Increasing Awareness and Education

Government Initiatives and Vaccination Programs

Rising Incidence of Influenza

Advancements in Vaccine Technology

Increased Healthcare Spending

Expanding Target Population

Globalization and Travel

Growing Geriatric Population

Public Health Preparedness

Collaborations and Partnerships

Regulatory Support

“Global Influenza Vaccines Market and Forecasts 2024 – 2032” presents an in-depth assessment of the global influenza vaccines market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global influenza vaccines market. The report also provides up-to-date historical market size data for the period 2018 – 2023 and an illustrative forecast to 2032 covering key market aspects like market value, volume analysis, and trends for influenza vaccines globally.

The report contains a deep analysis of the global influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the global influenza vaccines market. The report also explores a detailed analysis of the children and adults vaccinated with influenza vaccines globally from 2018-

2023 and forecasts to 2032. It provides essential insights into influenza vaccines market revenue for the top 27 regional and national, and forecast until 2032.

Key trends in terms of collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement are analyzed with details. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase. The report also investigates detailed insights about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan. The report also delivers a detailed assessment of the latest happenings in the influenza vaccines market globally. The report also examines the main market growth driving and challenges forces and also gives an all-round future outlook through 2032.

The report concludes with the profiles of the key players in the global influenza vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, influenza vaccines sales value analysis, and recent development.

Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated

on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and recent development.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global influenza vaccines market are determined with utmost precision.

Key and Emerging Players in the Global Influenza Vaccines Market are Listed Below:

1. Sanofi Pasteur
2. GlaxoSmithKline (GSK)
3. Seqirus (CSL Limited)
4. AstraZeneca
5. Mylan(Viatris)
6. BioDiem
7. Novavax
8. Medicago
9. Moderna Inc
10. Pneumagen
11. Daiichi–Sankyo
12. Altimune
13. FluGen
14. Imutex
15. EpiVax

16. Osivax

17. Emergex Vaccines

18. Versatope Therapeutics, Inc.

19. BIKEN Co., Ltd.

20. Gamma Vaccines Pty Ltd.

21. BiondVax Pharmaceuticals Ltd.

22. Hualan Biological Engineering Inc.

23. Shanghai Institute of Biological Products Co., Ltd.

The Report Analyses the Market on the Basis of Nationals and Presents the Forecast in Terms of Value and Volume for the Next 8 Years. Twenty-Seven Major Markets(27MM) Covered in the Report are as follows:

1. United States

2. Canada

3. Brazil

4. Germany

5. France

6. Italy

7. Spain

8. United Kingdom

9. Netherlands

10. Sweden
11. Denmark
12. Poland
13. Norway
14. Finland
15. Ireland
16. Belgium
17. Australia
18. New Zealand
19. Japan
20. China
21. India
22. South Korea
23. Thailand
24. Singapore
25. Hongkong
26. Malaysia
27. Indonesia

This Latest and Comprehensive th Global Influenza Vaccines Market Research Report 2024 provides:

Comprehensive research methodology of the global influenza vaccines market

Detailed and comprehensive market overview with important analyst insights

Insights into the market determinants stimulating the global influenza vaccines market

Analysis of the historical growth of the market size of the global influenza vaccines market from 2018 to 2023

The global influenza vaccines market size estimation and forecast from 2024 to 2032 and growth rate up to 2032

The market size of the 27 major influenza vaccines markets with eight years forecast

High-Level assessment of the overall persons being vaccinated with influenza vaccines

Scrutinizes the persons being vaccinated with influenza vaccines in the 27 major influenza vaccines markets with eight years forecast

Detailed assessment of the most recent happenings in the global influenza vaccines market

Comprehensive analysis of the regulatory framework including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan

Provides key trends with respect to collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement

Detailed observations of the most recent clinical trials of the influenza vaccines

A comprehensive list of the key players along with the analysis of their current vaccines portfolios, promising vaccines in the clinical development, sales value analysis, and recent development

An insightful analysis of the emerging players along with the analysis of their

promising vaccines in the clinical development, phase, platform technology, and recent development

This 2024 Report Helps Answer the Following Questions:

What is the current size of the global influenza vaccines market?

How big is the global market for influenza vaccines?

How much will this market be worth between 2024 and 2032?

How many persons being vaccinated with influenza vaccines globally during 2018 – 2032?

Which country is the leader in the global market for influenza vaccines?

How large is the market and what are the growth rates of the 27 most important markets for influenza vaccines?

What is the regulatory framework of the global influenza vaccines market?

What are the main drivers and challenges in the global influenza vaccines market?

What are the major deals happenings in the global influenza vaccines market?

Who are the top players and what are their activities, revenue, recent developments, and prospects?

Who are the emerging players?

What are some of the most prominent influenza vaccines currently in development?

What are the activities, phase, platform technology, and recent developments of the emerging players?

How will the industry develop in the forecast period 2024 – 2032?

Contents

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. GLOBAL NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES AND FORECAST (2018 – 2032)

5. GLOBAL INFLUENZA VACCINES MARKET REVENUE AND FORECAST (2018 – 2032)

6. GLOBAL INFLUENZA VACCINES MARKET SHARE AND Y–O–Y GROWTH (%)

6.1 Number of Persons Vaccinated with Influenza Vaccines Share, 2018 – 2032 (%)

6.2 Influenza Vaccines Market Share, 2018 - 2032 (%)

7. GLOBAL INFLUENZA VACCINES MARKET DRIVERS AND CHALLENGES

7.1 Market Drivers

7.2 Market Challenges

8. GLOBAL INFLUENZA VACCINES MARKET, BY GEOGRAPHY (VOLUME AND VALUE), 2018 – 2032

8.1 United States

8.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)

8.1.2 United States Influenza Vaccines Market Revenue (2018 – 2032)

8.2 Canada

8.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)

8.2.2 Canada Influenza Vaccines Market Revenue (2018 – 2032)

8.3 Germany

8.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)

8.3.2 Germany Influenza Vaccines Market Revenue (2018 – 2032)

8.4 France

8.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)

8.4.2 France Influenza Vaccines Market Revenue (2018 – 2032)

8.5 Italy

8.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.5.2 Italy Influenza Vaccines Market Revenue (2018 – 2032)

8.6 Spain

8.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.6.2 Spain Influenza Vaccines Market Revenue (2018 – 2032)

8.7 United Kingdom

8.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.7.2 United Kingdom Influenza Vaccines Market Revenue (2018 – 2032)

8.8 Netherlands

8.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.8.2 Netherlands Influenza Vaccines Market Revenue (2015 – 2027)

8.9 Sweden

8.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.9.2 Sweden Influenza Vaccines Market Revenue (2018 – 2032)

8.10 Denmark

8.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.10.2 Denmark Influenza Vaccines Market Revenue (2018 – 2032)

8.11 Poland

8.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027)

8.11.2 Poland Influenza Vaccines Market Revenue (2018 – 2032)

8.12 Norway

8.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.12.2 Norway Influenza Vaccines Market Revenue (2018 – 2032)

8.13 Finland

8.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.13.2 Finland Influenza Vaccines Market Revenue (2018 – 2032)

8.14 Ireland

8.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.14.2 Ireland Influenza Vaccines Market Revenue (2018 – 2032)

8.15 Belgium

- 8.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
- 8.15.2 Belgium Influenza Vaccines Market Revenue (2015 – 2027)
- 8.16 Australia
 - 8.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.16.2 Australia Influenza Vaccines Market Revenue (2018 – 2032)
- 8.17 New Zealand
 - 8.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.17.2 New Zealand Influenza Vaccines Market Revenue (2018 – 2032)
- 8.18 Japan
 - 8.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.18.2 Japan Influenza Vaccines Market Revenue (2018 – 2032)
- 8.19 Brazil
 - 8.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.19.2 Brazil Influenza Vaccines Market Revenue (2018 – 2032)
- 8.20 China
 - 8.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.20.2 China Influenza Vaccines Market Revenue (2018 – 2032)
- 8.21 India
 - 8.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.21.2 India Influenza Vaccines Market Revenue (2018 – 2032)
- 8.22 South Korea
 - 8.22.1 South Korea Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.22.2 South Korea Influenza Vaccines Market Revenue (2018 – 2032)
- 8.23 Thailand
 - 8.23.1 Thailand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.23.2 Thailand Influenza Vaccines Market Revenue (2018 – 2032)
- 8.24 Singapore
 - 8.24.1 Singapore Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.24.2 Singapore Influenza Vaccines Market Revenue (2018 – 2032)
- 8.25 Hongkong
 - 8.25.1 Hongkong Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.25.2 Hongkong Influenza Vaccines Market Revenue (2018 – 2032)
- 8.26 Malaysia
 - 8.26.1 Malaysia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)
 - 8.26.2 Malaysia Influenza Vaccines Market Revenue (2018 – 2032)

8.27 Indonesia

8.27.1 Indonesia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.27.2 Indonesia Influenza Vaccines Market Revenue (2018 – 2032)

8.28 Rest of the World (ROW)

8.28.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032)

8.28.2 ROW Influenza Vaccines Market Revenue (2018 – 2032)

9. RECENT DEVELOPMENT IN THE GLOBAL INFLUENZA VACCINES MARKET

10. REGULATORY FRAMEWORK OF THE GLOBAL INFLUENZA VACCINES MARKET

10.1 United States

10.2 Europe

10.3 Japan

11. MAJOR DEALS IN THE GLOBAL INFLUENZA VACCINES MARKET

11.1 Merger and Acquisitions

11.2 Collaboration Deals

11.3 Licensing Agreement

11.4 Exclusive Agreement

11.5 Distribution Agreement

12. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

12.1 Year 2023

12.2 Year 2022

13. KEY COMPANIES ANALYSIS

13.1 Sanofi Pasteur

13.1.1 Business Overview

13.1.2 Influenza Vaccines Portfolio

13.1.3 Influenza Vaccines Value Sales Analysis

13.1.4 Promising Influenza Vaccines in the Clinical Development

- 13.1.5 Recent Development
- 13.2 GlaxoSmithKline (GSK)
 - 13.2.1 Business Overview
 - 13.2.2 Influenza Vaccines Portfolio
 - 13.2.3 Influenza Vaccines Sales Value Analysis
 - 13.2.4 Recent Development
- 13.3 Seqirus (CSL Limited)
 - 13.3.1 Business Overview
 - 13.3.2 Influenza Vaccines Portfolios
 - 13.3.3 Influenza Vaccines Sales Value Analysis
 - 13.3.4 Promising Influenza Vaccines in the Clinical Development
 - 13.3.5 Recent Development
- 13.4 AstraZeneca
 - 13.4.1 Business Overview
 - 13.4.2 Influenza Vaccines Portfolio
 - 13.4.3 Influenza Vaccines Sales Value Analysis
 - 13.4.4 Recent Development
- 13.5 Gamma Vaccines Pty Ltd
 - 13.5.1 Business Overview
 - 13.5.2 Influenza Vaccines Portfolio
 - 13.5.3 Recent Development
- 13.6 Hualan Biological Engineering Inc
 - 13.6.1 Business Overview
 - 13.6.2 Influenza Vaccines Portfolio
 - 13.6.3 Recent Development
- 13.7 Shanghai Institute of Biological Products Co., Ltd.
 - 13.7.1 Business Overview
 - 13.7.2 Influenza Vaccines Portfolio
 - 13.7.3 Recent Development
- 13.8 Mylan
 - 13.8.1 Business Overview
 - 13.8.2 Influenza Vaccines Portfolio
 - 13.8.3 Recent Development
- 13.9 BioDiem
 - 13.9.1 Business Overview
 - 13.9.2 Influenza Vaccines Portfolio
 - 13.9.3 Recent Development
- 13.10 BIKEN Co., Ltd.
 - 13.10.1 Business Overview

13.10.2 Influenza Vaccine Portfolio

13.10.3 Recent Development

14. EMERGING PLAYERS

14.1 Novavax

14.1.1 Business Overview

14.1.2 Promising Influenza Vaccines in the Clinical Development

14.1.3 Recent Development

14.2 BiondVax Pharmaceuticals Ltd.

14.2.1 Business Overview

14.2.2 Promising Influenza Vaccines in the Clinical Development

14.2.3 Recent Development

14.3 Medicago

14.3.1 Business Overview

14.3.2 Promising Influenza Vaccines in the Clinical Development

14.3.3 Recent Development

14.4 Moderna Inc

14.4.1 Business Overview

14.4.2 Promising Influenza Vaccines in the Clinical Development

14.4.3 Recent Development

14.5 Pneumagen

14.5.1 Business Overview

14.5.2 Promising Influenza Vaccines in the Clinical Development

14.5.3 Recent Development

14.6 Altimune

14.6.1 Business Overview

14.6.2 Promising Influenza Vaccines in the Clinical Development

14.6.3 Recent Development

14.7 Daiichi Sankyo

14.7.1 Business Overview

14.7.2 Promising Influenza Vaccines in the Clinical Development

14.7.3 Recent Development

14.8 FluGen

14.8.1 Business Overview

14.8.2 Promising Influenza Vaccines in the Clinical Development

14.8.3 Recent Development

14.9 Imutex

14.9.1 Business Overview

- 14.9.2 Promising Vaccines in the Clinical Development
- 14.9.3 Recent Development
- 14.10 EpiVax
 - 14.10.1 Business Overview
 - 14.10.2 Promising Influenza Vaccines in the Clinical Development
 - 14.10.3 Recent Development
- 14.11 Versatope Therapeutics, Inc.
 - 14.11.1 Business Overview
 - 14.11.2 Promising Influenza Vaccines in the Clinical Development
 - 14.11.3 Recent Development
- 14.12 Emergex Vaccines
 - 14.12.1 Business Overview
 - 14.12.2 Promising Influenza Vaccines in the Clinical Development
 - 14.12.3 Recent Development
- 14.13 Osivax
 - 14.13.1 Business Overview
 - 14.13.2 Promising Influenza Vaccines in the Clinical Development
 - 14.13.3 Recent Development

15. APPENDIX

- 15.1 About DPI Research
- 15.2 Glossary of Terms

List Of Tables

LIST OF TABLES:

Table 6-1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2018 – 2032

Table 6-2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2024 – 2032

Table 6-3: Global Influenza Vaccines Market Share (Percent),2018 – 2023

Table 6-4: Global Influenza Vaccines Market Share Forecast (Percent),2023 – 2032

Table 10-1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 10-2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 10-3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 11-1: Merger & Acquisitions in the Influenza Vaccines Market

Table 11-2: Collaboration Deal in the Influenza Vaccines Market

Table 11-3: Licensing Agreement in the Influenza Vaccines Market

Table 11-4: Exclusive Agreement in the Influenza Vaccines Market

Table 11-5: Distribution Agreement in the Influenza Vaccines Market

Table 13-1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development

Table 13-2: Seqirus Promising Influenza Vaccines in the Clinical Development

Table 14-1: Novavax Promising Influenza Vaccines in the Clinical Development

Table 14-2: Biondavax Promising Influenza Vaccines in the Clinical Development

Table 14-3: Medicago Promising Influenza Vaccines in the Clinical Development

Table 14-4: Moderna Promising Influenza Vaccines in the Clinical Development

Table 14-5: Pneumagen Promising Influenza Vaccines in the Clinical Development

Table 14-6: Altimmune Promising Influenza Vaccines in the Clinical Development

Table 14-7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development

Table 14-8: FluGen Promising Influenza Vaccines in the Clinical Development

Table 14-9: Imutex Promising Influenza Vaccines in the Clinical Development

Table 14-10: EpiVax Promising Influenza Vaccines in the Clinical Development

Table 14-11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development

List of Figures:

Figure 4-1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand),2018 – 2023

Figure 4-2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast

(Thousand),2024 – 2032

Figure 5-1: Global Influenza Vaccines Market (Million US\$),2018 – 2023

Figure 5-2: Global Influenza Vaccines Market Forecast (Million US\$),2024 – 2032

Figure 8-1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-3: United States Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-4: United States Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-7: Canada Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-8: Canada Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-11: Germany Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-12: Germany Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-15: France Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-16: France Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-19: Italy Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-20: Italy Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-23: Spain Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-24: Spain Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-27: United Kingdom Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-31: Netherlands Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-35: Sweden Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-36: Sweden Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-39: Denmark Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-40: Denmark Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-43: Poland Influenza Vaccines Revenue Market (Million US\$),2018 – 2023

Figure 8-44: Poland Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-47: Norway Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-48: Norway Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-51: Finland Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-52: Finland Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-55: Ireland Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-56: Ireland Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-59: Belgium Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-60: Belgium Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-63: Australia Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-64: Australia Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

– 2032

Figure 8-65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-67: New Zealand Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-71: Japan Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-72: Japan Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2032

Figure 8-75: Brazil Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-76: Brazil Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8 77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-79: China Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-80: China Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-83: India Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-84: India Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-85: South Korea Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-86: South Korea Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-87: South Korea Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-88: South Korea Influenza Vaccines Market Revenue Forecast (Million US\$), 2024 – 2032

Figure 8-89: Thailand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-90: Thailand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-91: Thailand Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-92: Thailand Influenza Vaccines Market Revenue Forecast (Million US\$), 2024 – 2032

Figure 8-93: Singapore Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-94: Singapore Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-95: Singapore Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-96: Singapore Influenza Vaccines Market Revenue Forecast (Million US\$), 2024 – 2032

Figure 8-97: Hongkong Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-98: Hongkong Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-99: Hongkong Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-100: Hongkong Influenza Vaccines Market Revenue Forecast (Million US\$), 2024 – 2032

Figure 8-101: Malaysia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-102: Malaysia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-103: Malaysia Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-104: Malaysia Influenza Vaccines Market Revenue Forecast (Million US\$), 2024 – 2032

Figure 8-105: Indonesia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-106: Indonesia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-107: Indonesia Influenza Vaccines Market Revenue (Million US\$), 2018 – 2023

Figure 8-108: Indonesia Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 8-109: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023

Figure 8-110: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032

Figure 8-111: ROW Influenza Vaccines Market Revenue (Million US\$),2018 – 2023

Figure 8-112: ROW Influenza Vaccines Market Revenue Forecast (Million US\$),2024 – 2032

Figure 13-1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US\$),2018 – 2023

Figure 13-2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US\$),2024 – 2032

Figure 13-3: GSK Influenza Vaccines Net Sales Value (Million US\$),2018 – 2023

Figure 13-4: GSK Influenza Vaccines Net Sales Value Forecast (Million US\$),2024 – 2032

Figure 13-5: Seqirus Influenza Vaccines Net Sales Value (Million US\$),2018 – 2023

Figure 13-6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US\$),2024 – 2032

Figure 13-7: AstraZeneca Influenza Vaccines Net Sales Value (Million US\$),2018 – 2023

Figure 13-8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US\$),2024 – 2032

I would like to order

Product name: Global Influenza Vaccines Market and Forecasts 2024 – 2032

Product link: <https://marketpublishers.com/r/G8A78B0E1789EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8A78B0E1789EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970